This analysis suggested an explicit predictive value of GATA2 mRNA levels for biochemical recurrence and metastasis in PCa patients with a Gleason score of 7 (intermediate risk, Fig. 1i, j), but not for the low-risk cases with Gleason score ≤ 6 (Fig. S1k, i) or high-risk cases with Gleason score ≥ 8 (Fig. S1m, n). This evidence concerns the gene GATA2 and posterior cortical atrophy.